Double-blind, placebo-controlled, randomised, clinical trial of eicosapentaenoic acid in the treatment of mood disorders among middle-aged wome

Foundation Lucie et André Chagnon (Canada)0 个研究点目标入组 144 人开始时间: 2007年2月13日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Women between 40 and 55 years of age
•2. Moderate to severe psychological distress based on General Well-Being Scale (GWB) (score less than 72)
•3. Have a negative results on a pregnancy test and currently using an adequate method of contraception
•4. Provision of signed informed consent for participation

•1. Hamilton-21 score of 26 or more, or Patient Health Questionnaire (PHQ-9) score of 20 or more
•2. Past or current history of schizophrenia or bipolar I disorders
•3. Current or significant imminent risk of suicide or homicide
•4. Post-menopausal for more than five years
•5. Major medical disorders such as malabsorption disease, gastrectomy and acute pancreatitis
•6. Inherited or acquired disease of the haemostatic or the coagulation
•7. Medical conditions that interfere with the digestion and the absorption of medication
•8. Taking antihypertensive medications or suffer from hypercholesterolaemia or diabetes type two
•9. Endocrine diseases that could be linked to psychiatry
•10. Others medical causes that could be linked to psychiatry
•11. Have a current substance abuse disorders such as drugs (marijuana, cocaine, etc.) or alcohol (more than 40 g of alcohol by day)
•12. Fish allergies
•13. Have regularly consumed fish (more than three serving per week) in the last months
•14. Have taken antidepressant medication or hormone replacement therapy (HRT) or St-John?s Wort (Hypericum Perforatum) in the last six months before enrolment
•15. Current use of any drugs that thin blood such as aspirin, ibuprofen, heparin, clopidogel, warfarin, dalteparin, dipyrimadole, enoxaparin, ticlopidine, ginkgo or other anticoagulants

发起方

Foundation Lucie et André Chagnon (Canada)